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ABSTRACT
Objectives: Acute pancreatitis (AP) can initiate
systemic complications that require support in critical
care (CC). Our objective was to use the unified national
health record to define the epidemiology of AP in
Scotland, with a specific focus on deterministic and
prognostic factors for CC admission in AP.
Setting: Health boards in Scotland (n=4).
Participants: We included all individuals in a
retrospective observational cohort with at least one
episode of AP (ICD10 code K85) occurring in Scotland
from 1 April 2009 to 31 March 2012. 3340 individuals
were coded as AP.
Methods: Data from 16 sources, spanning general
practice, community prescribing, Accident and
Emergency attendances, hospital in-patient, CC and
mortality registries, were linked by a unique patient
identifier in a national safe haven. Logistic regression
and gamma models were used to define independent
predictive factors for severe AP (sAP) requiring CC
admission or leading to death.
Results: 2053 individuals (61.5% (95% CI 59.8% to
63.2%)) met the definition for true AP (tAP). 368
patients (17.9% of tAP (95% CI 16.2% to 19.6%))
were admitted to CC. Predictors of sAP were pre-
existing angina or hypertension, hypocalcaemia and
age 30–39 years, if type 2 diabetes mellitus was
present. The risk of sAP was lower in patients with
multiple previous episodes of AP. In-hospital mortality
in tAP was 5.0% (95% CI 4.1% to 5.9%) overall and
21.7% (95% CI 19.9% to 23.5%) in those with tAP
necessitating CC admission.
Conclusions: National record-linkage analysis of
routinely collected data constitutes a powerful resource
to model CC admission and prognosticate death during
AP. Mortality in patients with AP who require CC
admission remains high.
INTRODUCTION
Background/rationale
Acute pancreatitis (AP) is an inﬂammatory
disease of the pancreas with potentially devastat-
ing consequences for those who suffer a severe
Strengths and limitations of this study
▪ National record-linkage analysis of routinely col-
lected data constitutes a powerful resource to
model critical care (CC) admission and prognos-
ticate death during critical illness.
▪ This project brought together 16 electronic data
sources through a new record-linkage model for
Scotland and was at the forefront of the develop-
ment of the National Data Safe Haven in
Scotland.
▪ For individuals with AP who are not severely ill,
electronically formatted routinely recorded clin-
ical data are less comprehensive and this may
have led to a negative reporting bias for events
not sufficiently severe to need CC admission.
▪ Although we specifically conducted a data accur-
acy pilot, comparing electronic records with
hand-written notes in four separate study sites,
certain variables are likely to be more accurate,
for example automatically retrieved Wardwatcher
critical care data, than others for example
comorbidity and hospital immediate discharge
summaries.
▪ Although specific risk factors can be identified
that increase the risk of developing multiple
organ dysfunction in AP, it is not pragmatic or
straightforward to predict which individual
patients are likely to require CC based on their
routinely collected medical data.
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attack. Individual estimates of the incidence of AP range
from 10 to 78 per 100 000 per year.1–6 AP was found to be
the most common reason for hospitalisation with a gastro-
intestinal disorder in the USA in 2012.7 The estimated ﬁnan-
cial cost for AP-related care in the USA in 2004 was $3.7
billion, with AP resulting in 277 000 hospital admissions and
475 000 ambulatory visits.8 The ﬁnancial cost of treating AP
in the UK has been estimated at £200 million per year.9
In ∼20% of patients with AP, severe complications can
develop, which may evolve into multiple organ dysfunc-
tion syndrome (MODS) requiring critical care (CC)
support in high dependency (HDU) or intensive treat-
ment units (ITU).10 11 AP-MODS usually occurs rapidly,
and features of AP-MODS may be present at the time of
presentation to hospital.12 Between 2008 and 2010, 5%
of all available intensive care beds in Scotland were
taken up by patients with AP;9 in tertiary referral
centres, ITU bed occupancy may reach 9%.13 The epi-
demiological risk factors for developing organ dysfunc-
tion among individuals with AP are not known at
present. This knowledge will be important and useful to
identify high-risk patients by enhancing the stratiﬁcation
of disease severity, and to inﬂuence treatment decisions,
plan healthcare, allocate resources and inform trial
design. Therefore, there exists a need to understand
and identify risk factors for progression to AP-MODS
based on laboratory and clinical information leading up
to, and at the time of acute presentation to hospital.
The Farr Institute14 was conceived with the goal of cre-
ating a uniﬁed healthcare informatics infrastructure to
allow interested parties from government, academia,
industry, healthcare providers and other related organisa-
tions use linked electronic healthcare data on a national
scale in a secure, conﬁdential and streamlined way for
medical research within the UK. Given the substantial
healthcare burden of AP, the need for improved under-
standing and treatment of AP and the considerable inter-
est in the development of novel therapies for AP by us15
and others, the aim of this study was to harness the power
of the Farr Institute capabilities to elucidate the epidemi-
ology of AP with a focus on deﬁning the risk factors for
the development of organ failure in AP.
Objectives
Our speciﬁc objectives were to use the Farr Institute
infrastructure to:
1. characterise the epidemiology of AP in Scotland,
2. deﬁne the determinants of admission to CC and/or
death in AP and
3. describe the morbidity, length of CC stay, organ support
and mortality of patients with AP admitted to CC.
METHODS
Study design
We undertook a retrospective observational cohort study
of linked healthcare records from 16 electronic data
sources in Scotland.
Project structure and study management
The collaborative core project team consisted of a
project manager (PJ), clinician scientists with expertise
in AP (DJM and CS), an epidemiologist and statistician
from industry (UG and AL), national healthcare data
expertise (CD, ADM, FS), data managers, clinical infor-
mation governance (HW) and clinical statistics and epi-
demiology expertise (LC and PTD). A project board
(including lay membership) met quarterly to oversee
the project. The study protocol and analysis plan were
agreed in advance by the project board.
Ethical approval, patient confidentiality and data security
We obtained approvals from: National Services Scotland,
Privacy Advisory Committee; National Research Ethics
Service; National Research and Development Ofﬁce; the
local Research and Development Ofﬁce for each Health
Board; NHS Board Caldicott Guardians, via the
Caldicott Guardians’ National Scrutiny Process; Scottish
Intensive Care Society Audit Group (SICSAG) Steering
Group and General Practitioners (as Caldicott
Guardians). The study adhered to strict information gov-
ernance and security protocols. All primary data were
held within the NHS Scotland Information Services
Division (ISD) National Safe Haven with access restricted
to two named statisticians from the University of Dundee
(LC and PTD). Industry partners did not have sight of
patient-level data at any stage.
Setting and data sources
The study cohort consisted of all patients who had a
general or acute inpatient or day case record of AP in
any coding ﬁeld, coded as K85 under ICD10 K85
(including K85.0 Idiopathic acute pancreatitis; K85.1
Biliary acute pancreatitis; K85.2 Alcohol-induced acute
pancreatitis; K85.3 Drug-induced acute pancreatitis;
K85.8 Other acute pancreatitis; K85.9 acute pancreatitis,
unspeciﬁed), occurring in any of four NHS Health
Board areas in Scotland between 1 April 2009 and 31
March 2012. The ﬁrst episode for any one individual
occurring in that time period was taken as the index
episode. The combined total population of the four
Health Boards was 2 063 511 (48.9% of the population
of Scotland aged 18 years and over) at the midpoint of
the study, and included large conurbations and rural
areas. For each patient, data were collected from
Accident and Emergency attendances (A&E2 database),
Scottish Morbidity Record 00 (SMR00) Outpatient atten-
dances, SMR01 (General/Acute inpatient and day
cases), SMR04 (Mental Health inpatient and day cases),
SMR99 (Death registrations), Prescribing Information
System (primary care prescribing and dispensing),
SICSAG (CC), SCI Stores (laboratory test results) and
general practice data. Data were linked within the
National Safe Haven by an approved indexing process
based on a unique patient identiﬁer (the CHI number).
There were no exclusion criteria. A pilot study was per-
formed to assess the coding accuracy of AP in SMR01.
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Definitions and categories
AP was deﬁned as occurring when any elective or emer-
gency admission was coded as ICD10 K85 in any diagno-
sis ﬁeld. To account for inaccuracies of coding, true AP
(tAP) was predeﬁned as a subset of AP as: upper abdom-
inal pain or nausea or vomiting at presentation in the
clinical records and a serum amylase or lipase result
greater than three times the upper limit of the reference
range for that laboratory; or CT evidence of AP alone.
We predeﬁned severe AP (sAP) as a subset of tAP as:
tAP requiring admission to CC as a part of the same
episode or tAP resulting in death during that hospital
episode. CC was deﬁned as Level 2, Level 3 or both
inpatient care, also known as HDU and ITU, respect-
ively. Aetiology of AP was deﬁned at two levels: (1) in
the entire cohort, AP was attributed to gallstones if this
(or a related diagnosis, eg, cholecystectomy) was
recorded in any coding position; the remaining was
regarded as non-gallstone AP; (2) aetiology recorded
explicitly in hospital or GP records as gallstones, alcohol
or other less common causes. A GP visit was deﬁned as a
patient–practice interaction recorded as a visit event in
GP records, without being able to differentiate between
an actual medical consultation and other, for example
obtaining results, visiting the practice nurse or getting a
repeat prescription. The day of hospital admission was
deﬁned as day 0, and the next day after hospital admis-
sion was deﬁned as day 1 and so on. Overall hospital
mortality was deﬁned as death during a single episode
of AP occurring prior to hospital discharge. Overall
90-day mortality was deﬁned as any death occurring
within 90 days of the ﬁrst day of an episode of AP.
Variables
The primary outcome of interest was the development
of sAP (admission to CC, tAP death). Secondary out-
comes of interest were length of hospital stay in days,
length of CC stay in hours and days, maximum number
of organs supported, renal replacement therapy, ventila-
tor dependence, duration of enteral nutrition, hospital
acquired infection and death among those with sAP
admitted to CC. Potential risk factors included patient
demographics, measures of socioeconomic deprivation
(using the Scottish Index of Multiple Deprivation,16)
aetiology of AP, laboratory and clinical data at the time
of presentation to hospital, history of medication use
(prior to AP presentation) and clinical/disease history
up to the time of AP presentation, the latter two being
obtained from patients primary care records in the
12-month period prior to the index episode. Calcium
values were corrected for serum albumin concentration.
Record linkage
Data were linked using established probability and deter-
ministic matching techniques17 based on the Howard
Newcombe principles.18 Linkage was undertaken by a
trusted third party. A population spine, which contained
the personal identiﬁers of all individuals who have been
in contact with NHS Scotland, was used as an intermedi-
ary linkage tool. The process outlined was based on the
principles of data linkage outlined in the Scottish
Informatics Programme (SHIP) blueprint.19 The steps
of the process were: the indexing team was supplied the
CHI number of each of the cohort members by a single
data provider, for which they generated a different
record ID number across the range of data sets. Each
data provider received a ﬁle back with a list of patient
CHI numbers and unique person index ID numbers
speciﬁc to that data set, generated by the indexing team.
The data provider then attached the received index ID
number to the remaining content of the data set to be
provided for linkage and sent this to the research coord-
inator. The research coordinator sent the ﬁle to the
linkage agent, which is an automated computer pro-
gramme. The linkage agent received two ﬁles—all the
data sets including unique person ID numbers, plus a
master control ﬁle containing a master person ID and
unique person index ID numbers for the entire data set.
The linkage agent replaced all the data sets unique
person ID numbers with the master person ID number
on each of the content data ﬁles. The person analysing
the data had access to all the records belonging to an
individual across all the data sets without sight of per-
sonal identiﬁers.
Statistical methods
Descriptive analyses were performed according to stand-
ard principles using SAS V.9.3 and following the
STROBE criteria.20 Categorical variables were reported
as counts and percentages of the number of valid cases.
Continuous variables were described by either mean and
SD (for plausibly Normal data) or medians and quartiles
(non-Normal data). Between-group comparisons for uni-
variate analyses were assessed by independent samples t
test or Mann-Whitney U-test for Normal data and
non-Normal data, respectively. Differences in propor-
tions were tested by the χ2 test. To correct for extreme
outliers in an otherwise Normally distributed data set,
the 5% trimmed mean was used where stated; this value
is the arithmetic mean of data between the 5th and 95th
centile. Time-to-event variables were summarised using
medians and quartiles. Factors predicting the develop-
ment of sAP in the tAP cohort were modelled by logistic
regression with sAP as a binary dependent variable.
Variables were selected on the basis of known clinical
importance as well as backward elimination to identify
variables signiﬁcant at the 5% level. The ﬁnal model was
also assessed for goodness of ﬁt using Akaike’s
Information Criterion (AIC). Interactions between vari-
ables were entered and assessed by adding interaction
terms in the model. Predictive performance of the
model was assessed by estimation of the area under the
receiver operating characteristic curve (AUROC) and
calibration assessed using the Hosmer-Lemeshow test.
The ﬁnal model for prediction was based on the largest
AUROC. A number of parametric survival models were
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applied to identify factors that predict death during the
CC admission. AIC was used to decide on which model
was optimal. Model selection criteria were the same as
for the logistic regression model.
Imputation of missing data
For the logistic regression model, where clinically
important variables had less than 50% missing values,
multiple imputation was used to ensure that regression
analysis was robust, assuming that data were missing at
random. In practice, 19% of calcium measures at index
admission were imputed along with 35% of the primary
care ﬂag for alcohol dependency. All other variables in
the models were 100% complete.
RESULTS
Participants and univariate analysis
A total of 3340 individuals were identiﬁed as having an
AP-coded hospital admission, of which 2053 (61.5%)
met the case deﬁnition of tAP and were included in the
study. Figure 1 shows patient ﬂow in the study. The inci-
dence of an AP-coded hospital admission was 54.0 (95%
CI 41.1 to 70.9) per 100 000 per year; the incidence of
tAP was 33.1 (95% CI 24.4 to 46.9) per 100 000 per year
and the incidence of sAP requiring CC admission was
5.9 (95% CI 3.4 to 15.3) per 100 000 per year.
Demographic characteristics of the cohort are sum-
marised in table 1. Gender distribution was approxi-
mately equal across all categories and only increased
marginally towards a male preponderance for those with
sAP admitted to CC. The mean age of those with sAP
was signiﬁcantly higher than those who did not develop
severe disease. Gallstones were co-recorded in 43.8% of
the entire cohort coded as AP. The proportion of
patients with gallstone aetiology AP was higher for
females. The body mass index (BMI) of patients admit-
ted to CC was on average 1.1 kg/m2 higher than the
remainder of the tAP cohort. A disproportionate
number of tAP admissions (35.3%) were from the most
socially deprived quintile; this disproportion was simi-
larly observed in the subset of patients with sAP
(35.0%). The proportion of patients with tAP who
develop sAP and the proportion of those requiring CC
admission were not affected by social deprivation
(table 1).
Healthcare in general practice prior to study episode of AP
The GP consultation rate in the year preceding the
index AP episode was higher in the subset of patients
who died without being admitted to CC than those
requiring CC or those who did not develop sAP
(table 2). 25.6% of patients with an episode of tAP had
a previous episode of AP recorded in their GP-held
record, but a smaller proportion (18.5%) of those with
sAP had a previous AP episode documented. Although
the aetiology of AP could be attributed to gallstones in
43% of patients, gallstones were only known to be
present (in advance of the index episode) in 17.7% of
those with tAP. A similar proportion (16.5%) had been
admitted to hospital following alcohol misuse prior to
the index episode. The proportion with a prior episode
of alcohol-related hospital admission was not higher in
the sAP group.
There was a greater baseline comorbidity burden
among patients with sAP compared to the remainder of
the cohort. Pre-existing ischaemic heart disease (previ-
ous myocardial infarction (MI) or ischaemic heart
disease (IHD)/angina) was more prevalent in those with
sAP needing CC admission than those in the tAP cohort
as a whole (table 2). Pre-existing type 2 diabetes mellitus
was signiﬁcantly more prevalent in those with sAP requir-
ing CC compared to the tAP cohort. Similarly, chronic
obstructive pulmonary disease, hypertension and renal
failure (acute and chronic) were signiﬁcantly more
prevalent among the sAP cohort requiring CC admission
(table 2).
The following classes of drugs were prescribed more
frequently in those with sAP compared to those not
meeting the deﬁnition of sAP (nsAP): antidepressants,
calcium-altering drugs, neuroleptic agents, oral corticos-
teroids and statins. The proportions of patients taking
each class of drug are presented in table 3.
Endoscopic retrograde cholangiopancreatography had
been undertaken in the preceding year in 5.6% of those
admitted with tAP. This proportion was not higher in
those with sAP. Coronary stenting had been performed
in the preceding year more frequently in those with sAP
requiring CC (3.0%) compared to the nsAP cohort
(1.0%; table 3).
CC admission
Of 2053 patients, 368 (17.9%) with tAP were admitted
to CC with a median of 1 day (IQR 0, 2) after admission
to hospital (table 4). The 5% trimmed mean for this
time interval was 1.8 days. 27.4% of patients had two or
more CC admissions in relation to one episode of AP
and 6.2% had three or more CC admissions. Median
(IQR) duration of stay for the ﬁrst CC admission was 68
(27, 139) hours. The duration of CC stay was slightly
longer when averaged over all CC admissions (median
72 hours, IQR (29, 156)), and when total (sum) CC stay
was calculated for any one individual AP episode (ie, epi-
sodes during which there was more than one CC stay),
the median (IQR) duration was 107 (45, 221) hours. An
individual patient with AP requiring CC admission used
6 (3, 11) days of CC care (table 5).
The median (IQR) APACHE II score on admission to
CC was 19 (14, 24). The number of organ systems
requiring support is presented in table 4. A small pro-
portion of patients with sAP (24/368 (6.5%)) were
admitted for close observation without any recorded
organ support. During the initial admission, cardiovascu-
lar support with vasopressors was used in 60.3% of
patients with sAP, but this value rose to 65.5% when all
CC admissions were considered. 13.9% required
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mechanical ventilation on the ﬁrst admission, rising to
18.1% when all CC admissions for that AP episode were
considered. 4.8% required invasive renal replacement
therapy at any point during CC admission.
Factors predicting sAP (admission to CC or death)
The results of the logistic model predicting sAP in those
with tAP are given in table 6. A lower calcium level
(−0.1 mmol/L) at admission signiﬁcantly increased the
odds of developing sAP by 17% (OR 1.17 (95% CI 1.08
to 1.26)). Patients previously admitted with AP were less
likely to need CC admission during a subsequent admis-
sion (OR 0.77 (95% CI 0.61 to 0.98) for one previous
visit). A history of angina or IHD increased odds of sAP
(OR 1.46 (95% CI 1.07 to 2.00)), as did hypertension
(OR 1.43 (95% CI 1.05 to 1.96)), in addition to a
primary care ﬂag for alcohol dependency (OR 1.68
(95% CI 0.83 to 3.41)). There was a signiﬁcant inter-
action of age with type 2 diabetes. Generally, younger
patients had a lower odds of sAP compared to those
aged over 80 years, whereas for those aged 30–39 years
with type 2 diabetes the odds were signiﬁcantly
increased (OR 18.85 (95% CI 1.36 to 90.84)). The odds
were still higher for those with type 2 diabetes as age
increased but lower than for the 30–39 age group. The
AUROC 0.68 and the Hosmer-Lemeshow test were
non-signiﬁcant.
Mortality
Overall in-hospital mortality was deﬁned for patients with
tAP only and was 102/2053 (5.0%). Overall 90-day mortal-
ity for the tAP cohort was 127/2053 (6.2%) and for the
Figure 1 Flow diagram showing the fate of all potential participants in the study. AP, acute pancreatitis.
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Table 1 Demographics and comorbidity of patients admitted with acute pancreatitis
Patients coded
as ICD10 K85
(AP)
Patients meeting
definition of tAP
Patients
meeting
definition
of sAP
Patients with sAP
admitted to CC
(a subset of sAP)
Patients with sAP not
admitted to critical
care (a subset of sAP
that died without CC
admission)
Patients not
meeting definition
of sAP (nsAP)
Comparison of nsAP
versus sAP (statistically
significant, p value; χ2
test 1 df, unless
specified)
Number of cases
(N, % total cases) 3340 2053 (61.5) 390 (11.7) 368 (11.0) 22 (0.7) 1663 (49.8)
(N, % tAP) 390 (19.0) 368 (17.9) 22 (1.1) 1663 (81.0)
(N, % sAP) 368 (94.4) 22 (5.6)
Gender
(N female, % cases
within category)
1578 (47.2) 1028 (50.1) 183 (46.9) 172 (46.7) 11 (50) 845 (50.8) 0.167
Age in years
Mean (SD) 54.9 (18.5) 55.8 (18.5) 60.1 (18.0) 59.2 (17.9) 73.5 (13.5) 54.8 (18.5) <0.001
Body mass index (N=1466)
Median (1st, 3rd quartile) 26.7 (22.7, 31.6) 27.5 (23.0, 32.3) 28.4 (23.3, 33.1) 28.4 (24.1, 33.1) 22.1 (18.9, 30.7) 27.3 (22.9, 32.0) 0.227
Proxies for lifestyle (from GP records)
(N for which this recorded, %
total cases)
1657 (49.6) 1039 (50.6) 195 (50.0) 185 (50.3) 10 (45.6) 844 (50.8)
Overweight 238 (14.4) 145 (14.0) 47 (24.1) 43 (23.2) 4 (40.0) 98 (11.6) <0.001
Prior/known alcohol overuse 64 (3.9) 33 (3.2) 13 (6.7) 12 (6.5) 1 (10.0) 20 (2.4) 0.002
Smoking 615 (37.1) 364 (35.0) 85 (43.6) 80 (43.2) 5 (50.0) 279 (33.1) 0.006
Aetiology of AP
(N aetiology recorded, %) 3340 (100) 2053 (100) 390 (100.0) 368 (100) 22 (100) 1663 (100)
Gallstones (N, % of
recorded)
1482 (44.4) 919 (44.8) 171 (43.9) 165 (44.8) 6 (27.3) 748 (45.0) 0.686
Alcohol+other non-gallstone*
(N, % of recorded)
1877 (55.6) 1134 (55.3) 219 (56.1) 203 (55.2) 16 (72.7) 915 (55.0)
Social deprivation quintile
Most deprived 1 1209 (36.4%) 720 (35.3%) 136 (35%) 128 (34.9%) 584 (35.4%) Between groups
(N, % within category)
2 704 (21.2) 412 (20.2) 79 (20.3) 72 (19.6) 333 (20.2) 0.971 (χ2 test 1 df trend)
3 543 (16.3) 327 (16) 66 (17) 65 (17.7) 261 (15.8)
4 442 (13.3) 283 (13.9) 51 (13.1) 48 (13.1) 232 (14.0)
Most affluent 5 424 (12.8) 299 (14.6) 57 (14.7) 54 (14.7) 242 (14.6)
Duration of continuous inpatient stay, days
Median (1st, 3rd quartile) 5 (3, 11) 6 (3, 11) 16 (9, 31) 16 (10, 32) 6 (2, 20) 5 (3, 8) <0.001 (Wilcoxon)
Bold typeface signifies p<0.05.
*Exact proportion of alcohol diagnosis not possible for the entire cohort—see text for discussion.
AP, acute pancreatitis; CC, critical care; nsAP, not meeting definition of sAP; sAP, severe AP; tAP, true AP.
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Table 2 Healthcare prior to index AP admission
Patients
coded as
ICD10 K85
(AP)
Patients
meeting the
definition of
tAP
Patients
meeting the
definition of
sAP
Patients with
sAP admitted
to CC
(sAP-CC)
Patients with
sAP not
admitted to
CC
Patients not
meeting the
definition of sAP
(nsAP)
Comparison of nsAP
versus sAP (statistically
significant, p value; χ2 test 1 df,
unless specified)
Number of cases
(N, % total cases) 3340 2053 (61.5) 390 (11.7) 368 (11.0) 22 (0.7) 1663 (49.8)
Patients attending GP in year prior to admission
(N, % total cases) 618 (18.5) 317 (15.4) 48 (12.3) 42 (11.4) 6 (27.3) 269 (16.2)
Number of GP visits in year prior to admission (GP attendees only)
Median (1st, 3rd
quartile)
5 (2, 11) 5 (2, 10) 7 (3, 13) 5 (2, 12) 12 (7, 18) 5 (2, 9) 0.075 (Mann-Whitney U-test)
A&E attendances in year prior to admission
Median (1st, 3rd
quartile)
1 (1, 3) 1 (1, 2) 1 (1, 2) 1 (1, 2) 2 (1, 4) 1 (1, 2) 0.745 (Mann-Whitney U-test)
Hospital inpatient stays in year prior to admission
Median (1st, 3rd
quartile)
1 (0, 2) 1 (0, 3) 1 (0, 2) 1 (0, 2) 2 (0, 4) 1 (0, 2) 0.119 (Mann-Whitney U-test)
Hospital outpatient visits in year prior to admission
Median (1st, 3rd
quartile)
1 (0, 3) 1 (0, 3) 1 (0, 3) 1 (0, 3) 1 (0, 2) 1 (0, 3) 0.202 (Mann-Whitney U-test)
Number of previous admissions with AP
Median (1st, 3rd
quartile)
2 (1, 3) 1 (1, 2) 1 (1, 2) 1 (1, 3) 1 (1, 2) 1 (1, 3) 0.045 (Mann-Whitney U-test)
Previous diagnoses or admissions
Acute pancreatitis 968 (29.0) 525 (25.6) 72 (18.5) 71 (19.3) 1 (4.5) 453 (27.2) <0.001
(N, % within category)
Gallstones 628 (18.8) 364 (17.7) 61 (15.6) 58 (15.8) 2 (13.6) 303 (18.2) 0.230
Alcohol-related
psychiatric admission
757 (22.7) 338 (16.5) 59 (15.1) 56 (15.2) 3 (13.6) 279 (16.8) 0.429
Hypertension 942 (28.2) 595 (29.0) 152 (39.0) 143 (38.9) 9 (40.9) 443 (26.6) <0.001
Ischaemic heart
disease
539 (16.1) 334 (16.3) 102 (26.2) 95 (25.8) 7 (31.8) 232 (14.0) <0.001
Myocardial infarction 223 (6.7) 146 (7.1) 48 (12.3) 45 (12.2) 3 (13.6) 98 (5.9) <0.001
Stroke or TIA 226 (6.8) 139 (6.8) 41 (10.5) 38 (10.3) 3 (13.6) 98 (5.9) 0.001
Hypercholesteraemia 197 (5.9) 125 (6.1) 21 (5.4) 21 (5.7) 0 104 (6.3) 0.518
DM type 2 not on
insulin
471 (14.1) 267 (13.0) 79 (20.3) 79 (21.5) 0 188 (11.3) <0.001
DM type 2 treated
with insulin
57 (1.7) 20 (1.0) 6 (1.5) 5 (1.4) 1 (4.5) 14 (0.8) 0.208
DM type 1 113 (3.4) 45 (2.2) 9 (2.3) 9 (2.4) 0 36 (2.2) 0.862
DM (unspecified) 124 (3.7) 66 (3.2) 19 (4.9) 18 (4.9 1 (4.5) 47 (2.8) 0.039
Asthma 345 (10.3) 198 (9.6) 45 (11.5) 43 (11.7) 2 (9.1) 153 (9.2) 0.159
COPD 313 (9.4) 180 (8.8) 47 (12.1) 40 (10.9) 7 (31.8) 133 (8.0) 0.011
Continued
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sAP cohort was 100/390 (25.6%). In-hospital mortality
among sAP admitted to CC was 80/368 (21.7%), of
whom 54/368 (14.7%) died in CC and 26/368 (7.1%)
died in hospital after discharge from CC (table 5).
Patients who died in CC died after a median (1st, 3rd
quartile) of 70 (25–371) hours after CC admission
(table 5). The median time from hospital admission to
death for those dying in CC was 82 (26 371) hours, from
which it can be inferred that the median time between
admission to hospital and admission to CC was 12 hours
(table 5). Patients who died in hospital after discharge
from CC died after a median (1st, 3rd quartile) of 9.9
(5.1–21.9) days and mean 23.0 days after CC admission.
Twenty-two patients with sAP died in hospital without
being admitted to CC after a median (1st, 3rd quartile)
of 4.5 (2.0–18.0) days and mean of 12.0 days. The spe-
ciﬁc reasons why patients with sAP in this subgroup were
not admitted to CC are not known. None of these
patients had advanced malignancy recorded as a cause
or contributor on their death certiﬁcate. As a surrogate
to identify nursing home residents who may not have
been suitable for CC, we examined place of residence.
All 22 were admitted from private residence rather than
a nursing home and 2 of 22 lived alone. Since pre-
hospital and early mortality in sAP is greater in rural
areas,21 we examined postcodes for this patient sub-
group. Of 22 patients, 20 were from urban postcodes.
The mean±SD age of these 22 patients was 74±14 years
and median (range) was 72 (46–92) years. The median
BMI (1st, 3rd quartile) for these 22 patients was signiﬁ-
cantly lower (22.1 (18.9–30.7)) than the respective mea-
sures for the remainder of the tAP cohort.
Risk of death after CC admission
The results of ﬁtting the parametric Gamma model
(lowest AIC) are provided in table 7 and ﬁgure 2.
Generally, negative regression coefﬁcients indicate
factors that shorten the time to death. The only factor
that was positive was T2 DM, which gave a time ratio of
2.99 (95% CI 0.42 to 21.28). This indicates that the time
to death was threefold longer in those with T2 DM.
There were very signiﬁcant associations of shortening of
time to death with thyroid/parathyroid history
(TR=0.003, 95% CI 0.001 to 0.012) and history of coron-
ary artery stent in previous year (TR=0.049, 95% CI
0.014 to 0.168). For each unit increase in APACHE II
score, there was a 29% reduction in time to death
(TR=0.71, 95% CI 0.48 to 1.05), whereas for each add-
itional prior CC admission, the time to death reduced
by 34% (TR=0.66 95% CI 0.37 to 1.19). Finally, for each
increase in age by 1 year, the time to death reduced by
4% (TR=0.96 95% CI 0.92 to 1.01). Probabilities esti-
mated from the Gamma model were very close to the
Kaplan-Meier estimates of survival.
DISCUSSION
AP is associated with a high mortality, shortens overall
life expectancy in survivors22 and constitutes a
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Table 3 Prescription medications and procedures
Patients coded
as ICD10 K85
(AP)
Patients meeting
definition of tAP
Patients
meeting
definition of
sAP
Patients admitted
to CC (a subset of
sAP)
Patients with sAP
not admitted to CC
(a subset of sAP)
Patients not
meeting definition
of sAP (nsAP)
χ2 test of
sAP versus
nsAP
p Value
Number of cases
(N, % total cases) 3340 2053 (61.5) 390 (11.7) 368 (11.0) 22 (0.7) 1663 (49.8)
Prescribed drugs in year up to and including admission
Paracetamol 1557 (46.6) 917 (44.7) 202 (51.8) 188 (51.1) 14 (63.6) 715 (43.0) 0.001
(N, % within category)
Antidepressants 544 (16.3) 304 (14.8) 67 (17.2) 64 (17.4) 3 (13.6) 237 (14.3) 0.137
Calcium-altering drugs 466 (14) 283 (13.8) 78 (20) 74 (20.1) 4 (18.2) 205 (12.3) <0.001
Azathioprine 26 (0.8) 17 (0.8) 4 (1) 4 (1.1) 0 13 (0.8) 0.629
Carbemazepine 51 (1.5) 26 (1.3) 3 (0.8) 3 (0.8) 0 23 (1.4) 0.331
Oestrogens 158 (4.7) 107 (5.2) 21 (5.4) 21 (5.7) 0 86 (5.2) 0.818
Neuroleptic agents 876 (26.2) 512 (24.9) 116 (29.7) 108 (29.3) 8 (36.4) 396 (23.8) 0.017
Oral antidiabetic agents 247 (7.4) 144 (7) 33 (8.5) 32 (8.7) 1 (4.5) 111 (6.7) 0.209
Oral corticosteroids 206 (6.2) 133 (6.5) 35 (9) 28 (7.6) 7 (31.8) 98 (5.9) 0.025
Simvastatin 625 (18.7) 402 (19.6) 110 (28.2) 107 (29.1) 3 (13.6) 292 (17.6) <0.001
Statins (excluding
simvastatin)
56 (1.7) 35 (1.7) 11 (2.8) 10 (2.7) 1 (4.5) 24 (1.4) 0.058
Procedures in year up to and including admission
ERCP 267 (8.0) 115 (5.6) 18 (4.6) 18 (4.9) 0 97 (5.8) 0.352
(N, % within category)
Cholecystectomy 254 (7.6) 142 (6.9) 19 (4.9) 18 (4.9) 1 (4.5) 123 (7.4) 0.079
Thyroid/parathyroid
surgery
13 (0.4) 8 (0.4) 1 (0.3) 1 (0.3) 0 7 (0.4) 0.640
Coronary artery stent 40 (1.2) 27 (1.3) 11 (2.8) 11 (3.0) 0 16 (1.0) 0.004
Heart valve and/or
CABG
15 (0.4) 9 (0.4) 1 (0.3) 1 (0.3) 0 8 (0.5) 0.547
AP, acute pancreatitis; CABG, coronary artery bypass grafting; CC, critical care; ERCP: endoscopic retrograde cholangiopancreatography; nsAP, not meeting definition of sAP; sAP, severe AP;
tAP, true AP.
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considerable healthcare resource burden.7–9 13
Speciﬁcally, the evolution of persistent organ dysfunc-
tion requiring CC support has the most deleterious
short-term and long-term consequences in AP. Building
on previous work by others,23 24 in this cross-sectional
observational study, we have brought together 16 elec-
tronic healthcare records into a single national Safe
Haven overseen by the Farr Institute governance struc-
ture to conduct a detailed study of the development of
organ dysfunction and CC admission in AP.
These data conﬁrm a disproportionately high inci-
dence of AP in the most multiply deprived quintiles of
areas, in keeping with previous observations by us and
others,25 and that CC admission during an episode of
AP has a high (21.7%) mortality compared to that of
the overall cohort (5.0%). Patients who require CC
admission do so early in the disease course (at a median
of 1 day after admission) and experience a median total
of 6 days CC support per episode of AP. Factors inde-
pendently predictive of CC admission or death include a
history of angina, pre-existing hypertension, hypocalcae-
mia, fewer prior emergency admissions with AP and type
2 diabetes in young patients. The reasons for the associ-
ation with young patients with type 2 diabetes has not
Table 4 Admission to critical care
First CC admission All CC admissions
CC admissions during one continuous inpatient stay
1 or more 368 (100%)
2 or more 101 (27.4%)
3 or more 23 (6.2%)
4 or more 5 (1.4%)
5 1 (0.0%)
Days from hospital admission to first CC admission
Mean (95% CI) 3.03 (2.32 to 3.74)
5% trimmed mean 1.83
Median (1st, 3rd quartile) 1 (0, 2)
APACHE II score at CC admission
Median (1st, 3rd quartile) 19 (14, 24) 19 (14, 24)
Organs requiring invasive support at CC admission
0 123 (33.4%) 139 (27.9%)
1 124 (33.7%) 162 (32.5%)
2 96 (26.1%) 157 (31.5%)
3 22 (6%) 36 (7.2%)
4 3 (0.8%) 4 (0.8%)
Organ support required at CC admission
No immediate organ support given 24 (6.5%) 26 (5.2%)
Respiratory
Facemask/nasal cannulae 296 (80.4%) 382 (76.7%)
O2 less than 50% 206 (56.0%) 254 (51)
O2 50% or more 77 (20.9%) 111 (22.3%)
Continuous positive airway pressure 10 (2.7%) 17 (3.4%)
Endotracheal tube 46 (12.5%) 85 (17.1%)
Mechanical ventilator 51 (13.9%) 90 (18.1%)
Tracheostomy 2 (0.5%) 5 (1%)
Cardiovascular
Central venous catheter 136 (37.0%) 217 (43.6%)
Arterial line 186 (50.5%) 276 (55.4%)
Inotropes/vasopressors 222 (60.3%) 326 (65.5%)
Single vasoactive/antiarrhythmic drugs 37 (10.5%) 66 (13.3%)
Multiple vasoactive/antiarrhythmic drugs 15 (4.2%) 21 (4.2%)
Invasive cardiac output monitoring 10 (2.8%) 16 (3.2%)
Pulmonary artery catheter 0 (0%) 0 (0%)
Oesophageal Doppler waveform analysis 1 (0.3%) 3 (0.6%)
Peripheral pulse contour analysis 8 (2.2%) 10 (2)
Other method 1 (0.3%) 3 (0.6%)
Renal
Haemofiltration/dialysis 17 (4.6%) 24 (4.8%)
Neurological
Invasive neurological monitoring 0 (0%) 0 (0%)
CC, critical care.
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been ascertained from our data, despite our efforts to
do so; it is possible that this observation may reﬂect dif-
ferences in older persons, or reﬂect a confounder in
our data set that we have been unable to uncover. Once
admitted to CC, factors predictive of death included car-
diovascular stenting and thyroid or parathyroid surgery
within the previous year.
The overall mortality seen in our study is comparable
with that seen in other large epidemiological studies in
the UK,26 the USA,7 8 Taiwan,2 Japan4 and South
Africa.27 The mortality in the population of patients
with tAP requiring CC in the present cohort is somewhat
higher than many other reported studies, and certainly,
the APACHE II score on admission to CC was higher
than the average for the general ICU population in the
Scottish system.28 Patients admitted to CC who subse-
quently died were admitted to CC sooner (median
12 hours, mean 14 hours) after hospital admission than
the overall 5% trimmed mean for overall sAP-CC cohort
of 1.83 days (table 4). Therefore, non-survivors were
admitted to CC sooner after hospital admission than
eventual survivors. It is likely that this is a consequence
of more sAP in non-survivors triggering earlier CC
admission criteria. A second alternative explanation is
Table 5 Outcomes in critical care
First CC period All CC periods
Sum of CC periods in one
continuous inpatient stay
Admitted to CC
Number of patients 368 498 368
Died in CC 54 (14.7%)
Hours from CC admission to death
Median (1st, 3rd quartile) 70 (25, 371)
Mean 260
Hours from hospital admission to death
Median (1st, 3rd quartile) 82 (26 371)
Mean 264
Hours in CC
Median (1st, 3rd quartile) 68 (27, 139) 72 (29, 156) 107 (45, 221)
Mean 115 132 179
Days in CC
Median (1st, 3rd quartile) 4 (2, 7) 4 (2, 7) 6 (3, 11)
Mean 6.14 6.47 8.76
Ventilator-free days
Median (1st, 3rd quartile) 3 (2, 5) 3 (2, 5) 4 (2, 7)
Mean 4.18 4.01 5.43
Haemofiltration/dialysis (days)
Median (1st, 3rd quartile) 0 (0, 0) 0 (0, 0) 0 (0, 0)
6 (3, 8) on dialysis
Mean 0.94 0.96 1.30
8.1 on dialysis
Lowest pO2 on blood gas kPa
Median (1st, 3rd quartile) 9.9 (8.1, 11.4) 9.8 (8.2, 11.2)
Highest pO2 on blood gas kPa
Median (1st, 3rd quartile) 14.5 (11.2, 22.7) 15.4 (11.4, 23.6)
Lowest pCO2 on blood gas kPa
Median (1st, 3rd quartile) 5.1 (4.4, 6.0) 5.3 (4.5, 6.1)
Highest pCO2 on blood gas kPa
Median (1st, 3rd quartile) 5.4 (4.8, 6.2) 5.7 (5.0, 6.7)
Lowest pH on blood gas
Median (1st, 3rd quartile) 7.28 (7.15, 7.38) 7.28 (7.20, 7.37)
Highest pH on blood gas
Median (1st, 3rd quartile) 7.37 (7.29, 7.42) 7.36 (7.27, 7.42)
Highest FiO2 recorded %O2
Median (1st, 3rd quartile) 80 (50, 100) 90 (60, 100)
Highest creatinine mmol/L
Median (1st, 3rd quartile) 139 (91, 243) 144 (80, 272)
Highest bilirubin mmol/L
Median (1st, 3rd quartile) 26 (15, 68) 25 (14, 58)
CC, critical care.
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that it is possible that a faster evolution variant of AP is
more lethal, or that this subgroup of patients is more
susceptible to rapid evolution of disease. Finally, this
observation may reﬂect a delay in presentation to hos-
pital leading to increased mortality in those not present-
ing promptly for treatment.
Independent predictors of severe disease in tAP
included a history of angina and hypertension. It is
logical that patients with pre-existing chronic heart
disease would be at increased risk of death once they
develop organ dysfunction, and this is borne out in our
study by the association between coronary stenting in
the preceding year and risk of death after CC admission.
However, it is not as straightforward to link angina and
hypertension with an increased likelihood of needing
CC admission in the context of an AP episode. Angina
and hypertension in this scenario may be confounders,
acting as surrogate markers of other chronic health con-
ditions that directly reduce the threshold for developing
organ dysfunction requiring CC, or they may indicate a
lack of physiological compensatory reserve in critical
illness, such that for a given inﬂammatory insult there is
greater physiological derangement.
Our observation that a higher number of previous
admissions with AP reduces the risk for CC admission or
death during a subsequent AP episode is novel. It is
uncertain whether this is a result of increased individual
likelihood of developing systemic organ dysfunction with
particular severity of inﬂammatory insult, or whether fre-
quent A&E attenders, particularly with regard to alcohol
overuse, represent a different subset of patients.
Table 6 Logistic regression of factors predicting the
development of tAP to sAP (CC admission or death)
Parameter
Regression
estimate* SE
Intercept 2.499 1.069
T2 DM no insulin (yes/no) −0.298 0.442
Simvastatin 12 months prior
(yes/no)
0.221 0.151
Number of prior AP emergency
admission (+1 admission)
−0.259 0.123
Angina or IHD (yes/no) 0.379 0.161
Hypertension (yes/no) 0.360 0.161
Test result calcium† at index
admission (−0.1 mmol/L)
0.156 0.038
Age group (vs 80+)
18–19 −0.386 0.780
20–29 −0.867 0.630
20–29† T2 DM (yes/no) 1.235 1.279
30–39 −0.879 0.614
30–39† T2 DM (yes/no) 2.936 0.802
40–49 1.053 0.608
40–49† T2 (yes/no) 0.643 0.686
50–59 −0.342 0.596
50–59† T2 (yes/no) 0.292 0.576
60–79 −0.466 0.591
60–79† T2 (yes/no) 0.890 0.487
Alcohol flag† (yes/no) 0.521 0.360
*Increase in logodds.
†19% missing calcium, 35% missing alcohol; 98% relative
efficiency of multiple imputations with 10 imputations.
AP, acute pancreatitis; CC, critical care; DM, diabetes mellitus;
nsAP, not meeting definition of sAP; sAP, severe AP; tAP, true
AP.
Table 7 Factors that impact on time to death following CC from a Gamma prediction model
Parameter
Regression
estimate* SE
95% Confidence
limits χ2 p Value
Intercept 10.006 1.752 6.572 13.440 32.61 <0.0001
Age at index admission (+1 year) −0.037 0.022 −0.080 0.006 2.83 0.093
T2 DM (yes/no) 1.095 1.001 −0.867 3.058 1.20 0.274
Log (APACHE II) (+1 unit) −0.345 0.200 −0.736 0.046 2.99 0.084
Coronary artery stent within
1 year (yes/no)
−3.015 0.628 −4.245 −1.785 23.08 <0.0001
Thyroid/parathyroid (yes/no) −5.875 0.746 −7.336 −4.414 62.10 <0.0001
Number of CC stays in previous year
(+1 CC stay)
−0.414 0.299 −1.000 0.172 1.92 0.166
Gamma scale parameter 0.326 0.053 0.238 0.448
Gamma shape parameter 6.816 1.093 4.673 8.958
*Log of time to death ratio (negative represents a shorter time to death).
CC, critical care; DM, diabetes mellitus.
Figure 2 Probability plot (gamma model) of risk factors for
death after admission to critical care. CC, critical care; sAP,
severe acute pancreatitis.
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The relationship between ﬂuctuations in serum
calcium and pancreatitis is known29 and the association
between thyroid and parathyroid surgery and death after
CC admission and between hypocalcaemia and
calcium-altering drugs is not surprising. Hypocalcaemia
or hypercalcaemia is recognised in the Imrie30 and
Ranson31 scoring systems, and there is a wealth of pre-
clinical experimental evidence of deranged calcium sig-
nalling as a mechanism of pancreatic acinar cell injury.32
Strengths of study
The main strength of this study is the coalition of multiple
electronic data sources linked though a unique identiﬁer
on a national basis. Critical to this process was strict data
protection. This was achieved through the use of a centra-
lised protected safe haven and minimising the number of
individuals with access to the non-anonymised primary
data. Furthermore, industry partners could be fully
involved in the protocol design and processes surrounding
the data collection and depository without needing sight
of any primary data. Combining detailed inpatient CC
information collected at high temporal resolution and
integrating this with broad background data derived from
community data sources were achieved.
Limitations and bias
Limitations of this study include an inability to gain
information in electronic form on routinely recorded
clinical data from those inpatients who did not require
CC. This may have led to a negative reporting bias for
events that might be relevant to this study but not sufﬁ-
ciently severe to necessitate CC admission. In addition,
we are unable to ascertain exactly how many individuals
might have met criteria for CC admission but not admit-
ted due to advance directives or limited capacity.
A further limitation inherent to the study design based
on routinely collected data is the relative lack of con-
ﬁrmation of the accuracy of source data entry. Although
we speciﬁcally conducted a coding accuracy pilot for the
diagnosis of AP, comparing electronic records with
hand-written notes in four separate study sites, and while
certain variables are likely to be highly accurate, for
example automatically retrieved Wardwatcher critical
care data, laboratory values and date of death on death
certiﬁcates, certain other ﬁelds are impossible to ratify
accurately. We include in the latter category comorbidity
and clinical information recorded in hospital discharge
summaries.
CONCLUSIONS
National record-linkage analyses from a wide variety of
routinely collected primary and secondary care data
sources are feasible and constitute a powerful resource.
Factors that predict sAP are distinct from those that
prognosticate mortality. Mortality in patients with AP
who require CC admission remains high.
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